Below is a summary of our recent news. Click any post title or the read more link below any story to see more!
A doctoral student at Widener University is doing research on Graves' disease and neuropsychiatric symptoms - if you have a few minutes, please check out the details below and participate if you can!
Did you know that your regular online shopping can help the GDATF fund its patient education and support programs? By purchasing through one of the following channels, online retailers will donate a portion of proceeds to the Graves’ Disease & Thyroid Foundation - at no cost to you!
Amazon Smile Program
A company based in England and Belgium has started enrolling patients for a Phase I clinical trial for a new Graves' disease therapy - we will definitely be watching this development very closely! Click here to read more.
ThyCa: Thyroid Cancer Survivors’ Association, Inc. has generously offered the GDATF an opportunity to do a seminar on Graves' disease during the 19th International Thyroid Cancer Survivors' Conference at the Hilton Los Angeles Airport Hotel! The event will take place on Saturday, October 22nd from 12:30 - 5:30 p.m. and will feature presentations from Dr. Raymond Douglas, Dr. Ira Lesser, and Dr. Andrew Gianoukakis.
Please click here to register!
If you or a loved one is a thyroid cancer survivor and you would like to register for the entire conference, please click here for registration info. The cost to attend the full ThyCa conference is $50, with scholarships available to those with financial need. A huge thank you to THYCA for the opportunity - you can read more about their programs and services here: http://www.thyca.org/
Have you asked your endocrinologist about the American Thyroid Association's new guidelines for the management of hyperthyroidism?
“These ATA guidelines, written by an international and multidisciplinary task force, provide a significant update compared to the previous version published in 2011 because they integrate recent studies and developments in practice trends,” says Peter A. Kopp, MD, Editor-in-Chief of Thyroid and Associate Professor of Medicine, Division of Endocrinology, Metabolism, and Molecular Medicine, Northwestern University Feinberg School of Medicine, Chicago.
Task force chair Douglas Ross, MD, Massachusetts General Hospital, Boston, MA notes, “Some of the highlights of the 2016 guidelines are the changing paradigms for the evaluation and management of Graves’ disease with more reliance upon the measurement of thyrotropin receptor antibodies, new approaches for managing hyperthyroid patients desiring pregnancy, new approaches in the management of calcium metabolism prior to thyroid surgery, and a critical re-evaluation of the long-term toxicity of antithyroid drugs.”